Neosync ranked #30 Holder of Pervasive Neurotech Intellectual Property*

Neo­sync is an ear­ly stage com­pa­ny devel­op­ing a new treat­ment  for major depres­sion based on Tran­scra­nial Mag­net­ic Stim­u­la­tion (TMS). The treatment–named NEST (Neo­sync EEG Syn­chro­nized TMS) and under­go­ing clin­i­cal trials–is based on the idea that depres­sion patients tend to have over­ly rhyth­mic brain activ­i­ty, leav­ing crit­i­cal brain regions in a low ener­gy state. Through NEST, brain activ­i­ty could be mod­u­lat­ed via TMS, and EEG rhythms be simul­ta­ne­ous­ly monitored.

• Loca­tion: New­ton, MA
• Num­ber of employ­ees: <100
• Per­va­sive neu­rotech US patent grants: 4
• Per­va­sive neu­rotech US pend­ing appli­ca­tions: 10

*Neo­sync ranked #30 in Sharp­Brains’ Per­va­sive Neu­rotech IP Strength Index thanks to patents such as:

• US8475354: Sys­tems and meth­ods for neu­ro-EEG syn­chro­niza­tion therapy
• US8480554: Sys­tems and meth­ods for depres­sion treat­ment using neu­ro-EEG syn­chro­niza­tion therapy
• US8465408: Sys­tems and meth­ods for mod­u­lat­ing the elec­tri­cal activ­i­ty of a brain using neu­ro-EEG syn­chro­niza­tion therapy

To learn more about Sharp­Brains’ take on the orga­ni­za­tion’s #Per­va­siveNeu­rotech IP port­fo­lio, and over­all data and trends, click on Per­va­sive Neu­rotech­nol­o­gy: A Ground­break­ing Analy­sis of 10,000+ Patent Fil­ings Trans­form­ing Med­i­cine, Health, Enter­tain­ment, and Busi­ness.